Singapore, March 26 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology (Farrer)
National Cancer Centre
National University Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Choo Su Pin
Dr Evelyn Wong Yi Ting
Dr Yong Wei Peng
Dr Jens Samol
Published by HT Digital Content Services ...